NCT03005210View on ClinicalTrials.gov

A Study of Sofosbuvir and Ledipasvir From Magicbuvir Plus 90/400 mg Tablets (Magic Pharma, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

December 31, 2016

Conditions
Healthy
Interventions
DRUG

Magicbuvir Plus

1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir

DRUG

Harvoni (fist dose)

1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir

DRUG

Harvoni (second dose)

1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir

Trial Locations (1)

11757

Genuine Research Center GRC, Cairo

Sponsors

Collaborators (1)

Magic Pharma, Egypt
All Listed Sponsors
collaborator

Magic Pharma, Egypt

UNKNOWN

lead

Genuine Research Center, Egypt

INDUSTRY